Patients with low skeletal muscle mass are at a higher risk of falling. Certain diabetes medications, particularly SGLT2 ...

From STAT’s Matthew Herper: Pfizer said this morning that it would stop development of danuglipron, its experimental oral GLP ...

Pooled annual prevalence of GLP-1 RA use was 0.1 percent from 2018 to 2021 and increased to 0.4 percent by 2022.

People taking GLP-1 drugs can decrease fat mass while minimizing muscle loss with a few key strategies that include proper supervision, and a protein-rich diet, the results of a new study suggest.

Capping more than two years of stock-gyrating drama, Pfizer said Monday that it would stop development of danuglipron, its ...

In summary, GLP-1 receptor agonists, originally used to treat diabetes, are now being explored for brain protection. Two ...

A study led by two undergraduate students at the University of Galway found that GLP-1 receptor agonists, a type of diabetes ...

The study supports prior research that found the same thing.

Dementia, including Alzheimer’s disease and related disorders, is one of the fastest-growing public health concerns globally. It currently affects over 55 million people and is expected to impact 139 ...

However, even with its relatively lower price compared to the US, the question remains — can she truly afford it? And if she ...

A statistically significantly lower risk of dementia or cognitive impairment was observed with GLP-1RAs, though not with SGLT2is or pioglitazone.

Trial confirms that oral semaglutide lowers cardiovascular risk in type 2 diabetes, regardless of SGLT2i use. Read more!